$PACB News

Blank Bio Closes $7.2M Seed Financing And Strategic Collaboration With Pacific Biosciences

Pacific Biosciences of California, Inc. 2026 Q1 - Results - Earnings Call Presentation

Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

Pacific Biosciences Sees FY2026 Sales $165.000M-$175.000M vs $173.371M Est

Pacific Biosciences Q1 Adj. EPS $(0.12) Beats $(0.14) Estimate, Sales $37.178M Miss $39.986M Estimate

PacBio And PerkinElmer Subsidiary Covaris Announce That A Joint Workflow Has Been Developed For Robust HiFi Sequencing Of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue Samples

Watching Pacific Biosciences of California; Hearing Zacks Healthcare Innovators Newsletter Mentions Stock As A Buy

Watching Pacific Biosciences of California; Hearing Zacks Healthcare Innovators Newsletter Mentions Stock As A Buy

Basecamp Research Selects PacBio HiFi Revio Sequencing To Generate Large-Scale Environmental And Host-Associated Metagenomic Data For Trillion Gene Atlas Project

Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

PacBio Announces the Appointment of Chris Gibson to the Board of Directors

Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB)

3 Unprofitable Stocks We Approach with Caution

Pacific Biosciences Of California Inc Files For Mixed Shelf; Size Not Disclosed

Why Is PacBio (PACB) Stock Soaring Today

PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research

Why The PacBio (PACB) Narrative Is Shifting Around Fair Value And Long Read Sequencing

PacBio (PACB): Buy, Sell, or Hold Post Q4 Earnings?

5 Must-Read Analyst Questions From PacBio’s Q4 Earnings Call